All times in IDT

B&D; Consulting's Debra Lappin will moderate a panel discussion entitled "Medical Innovation and U.S. Health Care Reform — In Concert or At Odds?" on June 16, 2010, at 2:10 p.m. IDT during the Israel Life Science Industry (ILSI) Biomed Conference.

This panel discussion will more closely look at health care reform, to what extent will reform support and advance investments in medical innovation in the U.S., what are the barriers and where are we now in relation to the multiple key components of the health care reform debate that may directly affect decisions to invest in innovation in the U.S. Leaders from PhRMA, BIO, AdvaMed and the Council for American Medical Innovation will examine these issues and take a closer look at whether or not the U.S. innovation ecosystem is poised to attract, retain and sustain investments, thereby improving lives and the health of the U.S. economy.

The role medical innovation plays — both in improving outcomes and creating jobs — was overlooked by most policymakers. Despite studies showing medical innovation will have a far-reaching impact on curing diseases, lowering health care costs while providing jobs, Congressional leaders did not focus on the huge potential opportunities in medical innovation. This conference will take a closer look at cardiology, vaccines, oncology, cell therapy, personalized medicine and metabolic diseases, and will focus on:

• The role of innovation, its source — industry or academia? Who will pay for it? — venture capital or large medical and biopharma companies?
• Regulatory changes and their impact on innovation.
• Does personalized medicine mean smaller target markets?
• Who is better suited to commercialize future "niche" products? Large players or innovative fully integrated companies. How would it impact business models?

To view the complete event brochure, please click here.